Osteoporosis is characterized by compromised bone strength and increase susceptibility to fracture. The problem of osteoporosis is increasing in Indonesia. The Indonesian Osteoporosis Guideline was developed to increase the awareness of medical practitioners in the detection and management of osteoporosis. Early detection and prevention is of paramount importance. Assessment of risk factors is an integral part of the management of osteoporosis.
INTRODUCTION
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. In 2001, the National Institute of Health (NIH) proposed a new definition for osteoporosis as a systemic skeletal disease characterized by compromised bone strength result in increase susceptibility to fracture. 1 The problem of osteoporosis will increase in developing countries, including Indonesia, with increased life expectancies and increased proportion of aged population. Data from a survey in 1990 showed that proportion of population with age of 55 or more was 9.2%, which is increased 50% compared to data from the survey of 1971. 2 The Indonesian Guideline of Osteoporosis was developed to increase awareness of specialists, general practitioners and patients, about the detection and management of osteoporosis in Indonesia. Both the healthcare professionals and the patients can choose the optimal investigation and treatment options for the disease.
SUMMARY OF METHODOLOGY OF GUIDELINES DEVELOPMENT
The Guidelines was developed by Indonesian Osteoporosis Association (Perhimpunan Osteoporosis Indonesia, PEROSI) and was officially launched during The 6 th Annual National Scientific Meeting of PEROSI in Malang, Indonesia on October 15, 2010.
SUMMARY OF RECOMMENDATIONS

Risk factors
Several conditions will increase the risk for osteoporosis. Risk factor evaluation is an important step in identifying patients with osteoporosis. (Table 1) Risks for osteoporotic fracture are mainly determined by age and bone density. Other risk factors for osteoporotic fractures vary in different ages including risk of fall, vision problems, immobilization, sedative drugs and calcium intake. 3, 4 Physical examinations for patients with osteoporosis include height and weight. Other examinations include gait, bone deformities, leg-length inequality, spinal tenderness, and thyroid glands. Blue sclera are found in patients with osteogenesis imperfecta, associated with deafness, ligament hyperlaxity, joint hypermobility, and teeth abnormalities. In rickets, physical examination shows short stature, bone pain, craniotabes, costochondral joint prominence, and bowing deformity of longbone. Patients with hypocalcemia may present with tetany. Band keratopathy, which results from calcium phosphate deposition in the cornea, may be found in patients with primary hyperparathyroidism. 5
Bone biochemical markers
Indication for bone biochemical marker measurement is to identify patients with osteoporosis risk, rapid bone loss, predict femoral fracture risk, to monitor patient with longterm steroid treatment, to evaluate treatment responses and study the pathogenesis of osteoporosis. Treatment with anti-resorptive agents will rapidly decrease bone remodeling, thus it can be detected using bone marker tests.
Bone formation markers include serum alkaline phosphatase, osteocalcin, procollagen-1-peptides, p1-carboxyterminal propeptide, and p1-N-terminal propeptide. Bone resorption markers include urinary hydroxyproline, pyridinoline, deoxypyridinoline, and collagen-1-N-terminal telopeptide. Several conditions should be considered in interpreting results of bone markers, such as renal function, circadian rhythm, age and other diseases. 6, 7 
Radiographic examination
Patients with osteoporosis should have a radiographic examination of the thoraco-lumbar spine to identify the presence of spinal fracture. However, plain radiographic examinations cannot detect early osteoporosis. Radiographic examinations have an important role in excluding other conditions such as bone metastasis, spondylitis, degenerative process, or primary malignancy on bone. 2 
Bone densitometry
Bone density test using dual energy x-ray absorptiometry (DXA) method is the standard test and widely used to measure the bone mineral density (BMD). This technique can be used to measure axial, peripheral and total body bone density. Indications for bone density test are to confirm diagnosis of osteoporosis, to calculate fracture risk and monitor treatment. 8 (Table 2) Results from BMD test using DXA technique are area bone density (gram/cm 2 ), T-score, and Z-score. T-score is the number of standard deviations by which the patient's BMD differs from the mean peak BMD for young normal subjects of the same gender. Z-score is the number of standard deviations by which the patient's BMD differs from the mean BMD for subjects of the same age. The World Health Organization (WHO) classifies the BMD based on the T-scores. 8 (Table 3) Fracture risk can be calculated using formula WHO FRAX Tool from the website www.shef.ac.uk/FRAX.
Education and Prevention
Regular physical exercise to maintain strength, flexibility and coordination of neuromuscular system may prevent falls. Adequate calcium and vitamin D intake, smoking and alcohol cessation should be advised for all patients with osteoporosis. The patient should also be informed regarding other diseases and drugs that may increase risk of osteoporosis. Patients who need long-term corticosteroid therapy should be treated with the lowest acceptable dose and should be discontinued as soon as possible. A patient with chronic inflammatory disease such as rheumatoid arthritis should be adequately treated to control the disease process. 2 
Pharmacologic treatment
Bisphosphonate antiresorptive agent
Bisphosphonates inhibit the action of osteoclasts. 
Surgical treatment
Surgical treatment is indicated in a patient with fracture, mainly hip fracture. In elderly with hip fracture, surgical treatment should be planned immediately in order to prevent long-term immobilization and further complications. The patient should also be treated with calcium and anti-osteoporosis agent after the operation. 2 
Treatment evaluation
BMD re-examination at 1 to 2 year intervals can be done to evaluate treatment responses in patients with osteoporosis. If the BMD can be maintained or remains stable in one yea, the treatment is successful and the bone resorption activity is suppressed. Bone metabolism markers can also be used to evaluate treatment responses, and can detect the changes earlier, within 3-4 months. 2 
CONCLUSION
Osteoporosis can be prevented with careful assessment of the risk factors. Since the management of osteoporosis requires high cost and long-term monitoring, it is recommended that early detection and prevention especially among high risk population.
